This is read by an automated voice. Please report any issues or inconsistencies here. See more from the L.A. Times in Google Search. Set us as preferred There was a time in the beginning of Sublime’s ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Ignacio Carranza is VP of Marketing at Jumbula, advising youth education providers on ...

For basketball gaming fans, it has been a long time since a major streetball-focused title entered the conversation. That changes on June 9 when NBA THE RUN officially launches, bringing fast-paced ...

LUBBOCK, Texas (NEWS RELEASE) - Catholic Charities of Lubbock will host its 3rd Annual Run to Remember, a family friendly 5K run/walk, in remembrance of our neighbors on the South Plains who are ...

I read your response to the woman who wondered why she should invest in Social Security when the stock market would have been far more lucrative (“If I had invested my Social Security in the S&P 500 I ...

Text has emerged revealing the Clarity Act compromise worked out between members of the Senate Banking Committee, which would allow crypto firms to keep pursuing stablecoin reward programs. As ...

Kenyan runner Sabastian Sawe made history by becoming the first athlete to run a marathon in under two hours in a competitive race to win the London Marathon. Sawe broke the world record to complete ...

Is Poke an OpenClaw for the rest of us? That’s the idea coming from a new startup offering an AI agent that you can access via iMessage, SMS, Telegram, and, in some markets, WhatsApp. The AI agent ...

EDMONDS, Wash. — Syreh Sonko is studying nursing at Edmonds College through Washington state's Running Start, but the program that's saving her nearly $30,000 in college costs may soon look different.

San Francisco Ballet is amid its second program of 2026, a sublime presentation called "Balanchine: Father of American Ballet." Three complementary dances exemplify genius choreographer George ...

Amgen’s decision to terminate its rocatinlimab collaboration with Kyowa Kirin follows the publication of data on Sanofi’s rival OX40 drug candidate amlitelimab. (iStock / Getty Images Plus) Amgen has ...